A phase IIa, randomised, double-blind, placebo-controlled trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease modifying therapy
Study Team: Nick Cunniffe, Chris McMurran, Will Brown, Alasdair Coles, Riddhima Gautam
Development of a patient reported outcome measure (PROM) for patients with inherited optic neuropathy (ION) [ION-PROM]
An observation study Assessing Remyelinating Measures with the Objective of Understanding Repair in multiple sclerosis and in demyelinating conditions of the central nervous system.
Study Team: Gioia Riboni Verri, Jonathon Holland, Alasdair Coles, Nick Cunniffe, Riddhima Gautam
Assessing Huntington’s Disease patients for ophthalmological abnormalities as a measure of disease stage.
- Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS) Study: Observational study to identify biomarkers of Alzheimer’s disease in people with Down’s syndrome.
- SPRINGER: Studying progressive remyelination in nerves by grading electrophysiological recovery
- Study Team: Nick Cunniffe, Chris McMurran, Trisha Mukherjee, Will Brown, Alasdair Coles
- PROSPAX: Understanding the progression over time of hereditary spastic paraplegia (HSP), ataxia and related conditions.
Study Team: Benson Chen, Patrick Yu Wai Man